Discussion
Johnson & Johnson)
HAND PRESENTATION, RECRUITMENT
The inactivated whole-virion SARS-CoV-2 vaccine, CoronaVac, has a good safety profile and can induce considerable humoral immunity against SARS-CoV-2The mRNA-based vaccines such as BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) or the viral vector-based vaccines such as ChAdOx1 nCoV-19 (AZD1222, Oxford/AstraZeneca), Gam-COVID-Vac (Sputnik V, Gamaleya Inst.) and Ad26.COV2.S (Johnson & Johnson) take the advantage of providing the SARS-CoV-2 S-RBD antigen directly through intracellular antigen processing and cross-presentation pathways which enable the CD4The COVID-19 tend to show transition to endemicity, lose virulence and exhibit less severe infectionsThe presence of a long-term T cell memory in COVID-19 patients has been validatedBasically, the increased levels of these molecules on the S1-stimulated memory T cells can be used as an indicator of stimulation and as a correlate of immunity inaugurated with CoronaVac. The memory T cell pool serves as a dynamic repository of antigen-experienced T cells. TParticulate adjuvants such as aluminum salts create a local inflammatory environment and induce the recruitment of innate immune cells which mediate the uptake and presentation of the antigenIn conclusion, the aluminum-adjuvanted inactivated whole-virion SARS-CoV-2 vaccine, CoronaVac, induced functional S1-specific memory T cell responses. Either after a short-term or an intermediate-term following the second dose of the vaccine, majority of the individuals harbored CD4